1. Pink Sheet

Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar

 
• By Emily Hayes

Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.

Merck & Co. Inc.’s enormous outcomes study TRA-2P TIMI 50 highlighted the benefits of the novel protease activated receptor-1 (PAR-1) antagonist vorapaxar as an add-on therapy after heart attack to help prevent additional events, but also showed a heightened risk of major bleeding, which could make it harder for the drug to get approved.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D